Medtronic's stent graft dazzles in postmarketing study; Retinal implant's U.S. launch coming soon;

@FierceMedDev: A French start-up nailed some major financing for its retinal implant - a $20M-plus Series A. Story | Follow @FierceMedDev

@MarkHFierce: TB Dx maker Oxford Immunotec launched a relatively-modest IPO but it gained steam in initial trading. Friday's story | Follow @MarkHFierce

> Medtronic ($MDT) reports a new round of positive postmarketing global data for its Endurant II AAA stent graft system. Item

> Second Sight's new Argus II retinal implant will become available for U.S. patients in several weeks. Story

> The CEO of MedVenture Technology is resigning, a year after Helix Medical bought the maker of minimally invasive surgical devices. Item

> Intelligent Implant Systems gained a 510(k) clearance in the U.S. for its Marauder Cervical-Thoracic Spinal surgical system. Item

Biotech News

@FierceBiotech: Welcome Galen Moore, the new managing editor of FierceBiotech, FiercePharma and FierceMedicalDevices! | Follow @FierceBiotech

@JohnCFierce: Whoa, FDA gets mighty cross with 23andMe, tackles Anne Wojcicki. Want to see what angry regulators look like? FDA warning letter | Follow @JohnCFierce

@DamianFierce: With $43M in the bank, startup Editas sets off in pioneering "molecular surgery" field. News | Follow @DamianFierce

@EmilyMFierce: Biota scraps preclinical antibiotics program as antimicrobial resistance grows. Story | Follow @EmilyMFierce

> Biotech pioneer in 'gene editing' launches with $43M in VC cash. Story

> Orexigen shares soar as long-delayed weight drug clears PhIII safety hurdle. News

> ARMO emerges from stealth mode, preps study of discarded Merck drug. Article

> Portola shoots for early FDA approval after nabbing 'breakthrough' status. Story

> Cubist surges on positive PhIII antibiotic study. Item

Pharma News

@FiercePharma: The weekend's best-read special report: Top 10 Pharma Companies by 2012 Revenue. Report | Follow @FiercePharma

@EricPFierce: FDA approves, buys GSK vaccine in case of H1N1 pandemic. More | Follow @EricPFierce

@CarlyHFierce: Voters in Switzerland turn down strict CEO pay limits. Story | Follow @CarlyHFierce

> 2014 deal outlook: Sanofi eyes $2.7B in buys; AZ analysts figure on bigger M&A. Report

> Who leaked the scary Copaxone numbers? Teva aims to find out. Story

> J&J's newly approved Olysio to rival Merck and Vertex entries in hep C market. Item

CRO News

> Indian CROs leap into U.S. with joint venture. News

> Pharmacyclics, J&J pick Catalent for blockbuster cancer drug. More

> ResearchDx reaches into India for contract diagnostics work. News

> Covance taps NeoGenomics for cancer trial diagnostics. Article

> Vietnam taps Quintiles to up its stake in global trials. Story

Biotech IT News

> Google begins hiring team to lead Calico. More

> Life sciences IT execs plan business intelligence spending blitz. News

> Lilly, Novartis and Pfizer sign up to improve Story

> Report finds inexcusable failings in government cybersecurity. Piece

> Novartis looks to data management vendors to slash costs. Article

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.